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Although Crohn’s disease is a chronic inflammatory disease of the gastrointesti-
nal tract, it can affect multiple organs behaving like a multisystem immune medi-
ated disease. The dysregulated immune system in patients with Crohn’s disease
leads to uncontrolled inflammation which primarily affects the gastrointestinal tract
but may also affect various extra-intestinal organs. With the increased incidence
and prevalence of Crohn’s disease, its extra-intestinal manifestations are increas-
ingly being seen in our clinical practice. The musculoskeletal, mucocutaneous,
ophthalmic, hepatobiliary, renal, cardiovascular and pulmonary manifestations of
Crohn’s disease have been reviewed in this chapter. Some of these extra-intestinal
manifestations are due to systemic inflammation, some of them are due to malab-
sorption of nutrients and bile salts, and some due to medications given for the
treatment of Crohn’s disease. These extra-intestinal manifestations of Crohn’s dis-
ease are seen in at least 25% of patients with Crohn’s disease. Some of them correlate
well with Crohn’s disease activity but the rest of them have no relation to the
activity of Crohn’s disease. Although most of the time the extra-intestinal features
are seen after the diagnosis of Crohn’s disease, they can precede or follow the
diagnosis of Crohn’s disease. Management of these extra-intestinal manifestations
varies as the ones associated with activity of Crohn’s disease respond to remission of
Crohn’s disease whereas the ones not related to the activity of Crohn’s disease
require specific treatments for those conditions.
Keywords: extra-intestinal manifestations of Crohn’s disease, musculoskeletal
manifestations of Crohn’s disease, mucocutaneous manifestations of Crohn’s
disease, ophthalmic manifestations of Crohn’s disease, hepatobiliary, renal,
cardiovascular and pulmonary manifestations of Crohn’s disease
1. Introduction
Crohn’s disease is an idiopathic chronic, relapsing inflammatory condition that
mainly affects the gastrointestinal tract but can also involve extra-intestinal sites. As
the incidence and prevalence of this disease is increasing, we are also seeing more
and more extra-intestinal features of this disease [1, 2]. Crohn’s disease and ulcera-
tive colitis are the two main forms of inflammatory bowel diseases and both of them
have extra-intestinal manifestations. In this chapter, we will be focusing on the
extra-intestinal features of Crohn’s disease.
The gastrointestinal tract plays an important role in immune regulation. The
innate and adaptive immunity becomes dysregulated in Crohn’s disease. This gen-
erally occurs in a genetically susceptible individual due to environmental factors
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and altered gut microbiota. As the immune homeostasis is disrupted, uncontrolled
inflammation occurs in the gut. The inflammatory process can become systemic and
other organs can be involved as well. At least 25% of patients with Crohn’s disease
develop extra-intestinal manifestations [3]. Joints, bones and skin are most com-
monly involved. Other organs of involvement include muscles, eyes, oral mucosa,
hepatobiliary system, kidneys and lungs [4]. Some of these manifestations correlate
with disease activity and some of them have no correlation with disease activity.
Most of the time joint, eye and skin involvement correlate with intestinal inflam-
matory disease activity. Active Crohn’s disease can reduce fertility in women due to
decreased ovarian reserve. This results in decreased anti-Mullerian hormone
(AMH) level in the blood in women above age 30 years with active Crohn’s colitis
compared to healthy control women [5]. Patients’ with Crohn’s disease have signif-
icantly increased risk of developing anxiety and depression, particularly in the year
after the initial diagnosis of Crohn’s disease [6]. The pooled prevalence of anxiety
and depression in Crohn’s disease was found to be 31% and 24.4% respectively in
a systematic review [7]. Extra-intestinal manifestations (EIMs) are more prevalent
in patients with Crohn’s colitis although these manifestations may precede the
development of colitis, be synchronous with colitis, follow the diagnosis of Crohn’s
disease or persist even after colitis subsides. Patients with one EIM are at
increased risk of developing another EIM. In fact, 25% of the patients have more
than one EIM.
2. Musculoskeletal manifestations
As mentioned before musculoskeletal system involvement is common and these
include arthalgia, arthritis, pseudoarthritis, hypertrophic osteoarthropathy,
osteopenia, osteoporosis, aseptic necrosis of the hip and other joints, psoas abscess,
osteomyelitis and sarcopenia. Peripheral arthalgia occurs in about 20% of patients
with Crohn’s disease and is strongly associated with Crohn’s colitis [8]. About 15 to
20% patients with Crohn’s disease develop arthritis [9]. Approximately 60 to 70%
of arthritis is peripheral large joint arthritis. Knees, ankles, wrists, elbows and hips
are most commonly affected. Oligoarticular arthritis affecting less than 5 joints is
seen in 6% of patients with Crohn’s disease, and polyarticular arthritis affecting 5 or
more joints affects 4% of patients with Crohn’s disease [10]. A minority of patients
with Crohn’s disease may develop symmetrical polyarthritis affecting proximal
interphalangeal, metacarpophalangeal, and metatarsophalangeal joints similar to
the presentation of rheumatoid arthritis. 1 to 6% of patients with Crohn’s disease
develop ankolysing spondylitis affecting the spine and sacroiliac joints. Patients
with ankolysing spondylitis present with low back pain and gradually they develop
spinal fusion over a period of time. As many as two-third of patients with Crohn’s
disease with ankolysing spondylitis are HLA-B27 positive [11]. Small joint
polyarthritis and ankolysing spondylitis can flare up without any increased activity
of Crohn’s disease. Pseudoarthritis presenting as diffuse joint aches can occur fol-
lowing glucocorticoids withdrawal. Aseptic necrosis of joints (particularly hip
joints) can occur in Crohn’s disease due to hypercoagulable state and fibrin
microclot formation occluding the epiphyseal capillaries [12]. Either short term high
dose or long term corticosteroid therapy can also predispose the patients with
Crohn’s disease to aseptic necrosis of bone (i.e. cellular death of bone) which can
cause severe pain and disability [13]. In one study, 2.1% of patients with inflamma-
tory bowel disease had aseptic necrosis of the hip on computerized tomography
[14]. Crohn’s disease leads to low mineral density which is seen even at time of
diagnosis. Proinflammatory cytokines like tumor necrosis factor, smoking, calcium
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and vitamin D malabsorption and low body mass index (BMI) are contributing
factors although use of glucocorticoids is the main risk factor [15, 16]. Osteopenia
(T score 1.0 to2.49) and osteoporosis (T score 2.5 and lower) are seen in 30 to
60% of patients with Crohn’s disease. 60% of patients with Crohn’s disease also
develop sarcopenia that is strongly related to osteopenia and osteoporosis [17].
















Cutaneous manifestations occur in almost one third of patients with Crohn’s
disease. Erythema nodosum (EN) and pyoderma gangrenosum (PG) are the
most common cutaneous lesions seen in Crohn’s disease although these lesions can
also be seen in other disorders [18]. EN appears as an erythematous subcutaneous
tender nodule, most commonly seen on the pretibial region (Figure 1). In Crohn’s
disease, EN is more commonly seen in females than in males. It tends to occur
during the first 2 years of clinical course and is associated with exacerbation of large
joint arthritis and colitis, and generally improves with the treatment of Crohn’s
disease [19]. It is recommended not to biopsy EN because of risk of scar tissue
formation.
PG generally presents as painful ulcers with sharply circumscribed and demar-
cated violacious borders and crater-like holes at the necrotic yellowish base, most
commonly seen on the extensor surface of the lower extremities but can occur
anywhere on the body [20]. Sometimes PG can present tender nodules or pustules
[21]. PG is a chronic debilitating skin disorder and is not associated with Crohn’s
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disease activity. Histologically it is a neutrophilic dermatosis characterized by infil-
tration of neutrophils into the skin. Pathergy phenomenon (i.e. formation of large
ulcers in response to minor trauma) is characteristic of PG. PG heals up with
cribriform scars (Figure 2).
Sweet’s syndrome (SS) is another neutrophilic dermatosis rarely associated with
Crohn’s disease. Patients present with painful erythematous or violaceous papular
or nodular lesions on the face, neck or upper extremity with abrupt onset of fever
and neutrophlic leukocytosis [22].
Oral mucosa can be affected in Crohn’s disease. Lips are the most common sites
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granulomatous involvement of the lips. Aphthous ulcers or stomatitis (AS) occurs
in 20 to 30% of patients with Crohn’s disease [24]. Pyostomatitis vegetans (PV) is
another rare lesion associated with Crohn’s disease. It is characterized by ‘snail
track’ shaped flat yellowish ulcers in the oral and gingival mucosa [25].
Another rare cutaneous manifestation of Crohn’s disease is metastatic Crohn’s
disease (MCD). It can present as papule, nodule, plaque or ulcer with a predilection
for skin folds, external genitalia (penis, vulva), perineum, infra-mammary area,
limbs and retroauricular area [26]. It is so called because of the presence of non-
caseating granuloma (histologically identical to the primary intestinal lesion) in the
skin that is remote from the gastrointestinal tract [27]. MCD can precede or develop
simultaneously with intestinal Crohn’s disease. No clear correlation is found
between MCD and intestinal Crohn’s disease activity [28].
The prevalence of psoriasis is 8 times higher in patients with Crohn’s disease
than that in the general population due to overlapping genetic and
immunopathogenic mechanisms [29]. There is also increased incidence of
epidermolysis bullosa acquisita and leucocytoclastic vasculitis in patients with
Crohn’s disease [30, 31]. Epidermolysis bullosa acquisita (EBA) appears as subepi-
dermal blistering skin lesion over the extensor aspect of the body, particularly on
trauma prone areas, and is associated with scarring, milia formation and skin fra-
gility. EBA occurs due to autoimmunity to type VII collagen present at the
dermoepidermal junction and is associated with symptomatic esophageal web for-
mation [32]. Leucocytoclastic vasculitis (LCV) is another very rare dermatologic
manifestation of Crohn’s disease and presents as palpable purpura over the lower
extremities and ankles [33]. EN, AS, PV, SS and LCV can be associated with
increased intestinal inflammatory activity.
Dermatologic manifestations secondary to malabsorption of nutrients can occur.
These include angular cheilitis due to riboflavin deficiency, purpura due to vitamin
K deficiency and acrodermatitis enteropathica (AE) due to zinc deficiency. AE
appears as eczematoid and psoriasiform patchy skin lesions on the extremities and
peri-orificially. AE can also cause alopecia [34].
Patients with Crohn’s disease are at increased risk of developing melanoma of
the skin [35].
Certain skin lesions are due to the medications used to control Crohn’s disease.
Anti-tumor necrosis factor (TNF) agents can cause paradoxical psoriasiform rash
over the palmar aspect of hands, planter aspects of feet, flexures and scalp in about
5% of patients [36]. Risk factors for developing this rash include female sex, obesity,
smoking (active or past), short duration of disease and family history of inflamma-
tory skin disease [37]. The pathogenesis of development of this anti-TNF-induced
psoriasiform rash is exactly not known. But increased concentration of IL-17/IL-22
expressing Th17 cells and interferon (IFN)- Υ-expressing Th1 cells are seen in the
rash [36, 38]. IFN- α may also play a role in the formation of this rash. Normally
TNF decreases the production of IFN- α by inhibiting the maturation of
plasmacytoid dendritic cells. Anti-TNF therapy may lead to overproduction of IFN-
α [39]. Increased concentration of IFN- α protein is found in anti-TNF associated
psoriasiform rash. Another mechanism could be anti-TNF-induced patchy cutane-
ous immune suppression leading to the formation of psoriasiform rash [40].
Other non-psoriasiform skin lesions due to anti-TNF agents include local pru-
ritic skin erythema at the site of infusion, eczematiform skin lesions, xerosis cutis,
palmoplantar pustulosis, viral and bacterial infections of the skin [41]. Long et all
found in a retrospective study that ant-TNF therapy may increase the risk of
melanoma, and thiopurines may increase the risk of non-melanoma skin cancer
(basal cell cancer, squamous cell cancer) [42]. The mucocutaneous manifestations
are outlined in Table 1.
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4. Ophthalmic manifestations
Eyes can be involved in 12% of patients with Crohn’s disease [43]. Ocular
involvement occurs more commonly in patients with colonic or ileocolonic Crohn’s
disease than in patients with isolated small bowel Crohn’s disease [44]. Frequently,
patients with ocular involvement also have peripheral large joint arthritis and EN.
The common ophthalmic manifestations include episcleritis, scleritis, uveitis, non-
specific follicular conjunctivitis and blepharitis [45]. Rarely, orbital myositis and
optic neuritis can occur. Patients with episcleritis and scleritis present with red
tender eyes. Patients with uveitis present with deep eye pain, red eyes with
circumcorneal congestion, meiosis, headache, blurring of vision and photophobia.
Patients with uveitis should be seen by an ophthalmologist emergently. Uveitis in
patients with Crohn’s disease is generally bilateral, posterior, insidious in onset,
chronic and 4 times more common in females than in males [46]. Patients with
small bowel Crohn’s disease may also present with night blindness secondary to
vitamin A malabsorption and deficiency. The ophthalmic manifestations are

























• increased risk of
developing





• Paradoxical psoriasiform rash due to anti-TNF
• local pruritic skin erythema at the site of
infusion
• Eczematiform skin lesions
• Xerosis cutis
• Palmoplantar pustulosis
• Viral and bacterial infections of the skin
• Increased risk of melanoma due to anti-TNF
• Increased risk of non-melanoma skin cancer
(basal cell cancer, squamous cell cancer) due
to thiopurines
Table 1.
Mucocutaneous manifestations of Crohn’s disease.
Ophthalmic manifestations due to disease Ophthalmic manifestations due to malabsorption







Night blindness due to vitamin A deficiency
Table 2.
Ophthalmic manifestations in Crohn’s disease.
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5. Hepatobiliary manifestations
Crohn’s disease can affect both liver and biliary tract. Some of the manifestations
are directly related to the disease process and some are secondary to medications
used in Crohn’s disease. Non-alcoholic hepatic steatosis (NAHS) is the most fre-
quent hepatobiliary manifestation that is secondary to intestinal inflammation and
metabolic factors [47]. Sagami et all found in a retrospective study that patients
with Crohn’s disease and NAHS had higher rate of remission and longer surgery free
interval [48]. About 2% of patients with Crohn’s disease develop primary sclerosing
cholangitis (PSC), and 5 to 10% of patients with PSC have Crohn’s disease [49]. PSC
is a progressive inflammatory, fibrosing and stricturing disease involving both
intrahepatic and extrahepatic bile ducts in more than 80% of cases. In about 10% of
cases, only intrahepatic bile ducts are involved and in less than 5% of cases, only
extrahepatic bile ducts are involved. Patients with PSC remain asymptomatic for
many years. They are generally detected by finding abnormal liver function test.
When symptomatic, they generally present with itching jaundice, right upper
quadrant pain, fever and chills. Magnatic resonance cholangiopancreatography
(MRCP) rather than Endoscopic retrograde cholangiopancreatography (ERCP) is
now considered as diagnostic test of choice as it is non-invasive, can reduce the risk
of hospitalization by 10%, and can visualize the liver [50]. It shows ‘stricturing and
beading’ appearance of both extra-hepatic and intra-hepatic bile ducts. Liver biopsy
is not required if imaging studies are suggestive of PSC. Liver histology may show
lymphocytic infiltrate of bile duct, bile ductopenia, and periductal concentric
fibrosis giving ‘onion skin’ appearance but no histological appearance is pathogno-
monic of PSC. Patients with PSC are at increased (10–15%) risk of developing
cholangiocarcinoma. But colon cancer risk does not seem to be increased in patients
with PSC and Crohn’s colitis [51]. Other hepatobiliary manifestations of Crohn’s
disease include cholelithiasis, granulomatous hepatitis, portal vein thrombosis and
secondary amyloidosis [52–54]. Patients with Crohn’s disease have 2 fold increased
prevalence of gallstone formation than general population. According to Crohn’s
and colitis foundation of America, up to one third of patients with Crohn’s disease
may develop gallstones which could be cholesterol-rich stones or pigment stones. In
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without ileal disease/resection) leading to the formation of cholesterol-rich gall-
stones [55]. In patients with ileal disease/resection, bile acid malabsorption initially
causes bile acid-induced diarrhea. Bile acid pool slowly decreases and it leads to
cholesterol supersaturated bile and cholesterol-rich stone formation. Bile acid mal-
absorption also induces enterohepatic circulation of bilirubin and increases the rate
of secretion of bilirubin into bile. This may help formation of pigment stone [56].
6. Renal manifestations
Renal and urinary tract involvement can occur rarely in Crohn’s disease.
Nephrolithiasis, IgA nephropathy, membranous glomeruloneohritis, tubuloin-
terstitial nephritis and amyloidosis are the most frequent involvement [57]. Calcium
oxalate stone is formed in the kidneys and urinary tract because of hyperoxaluria. In
extensive Crohn’s disease of small bowel or intestinal resection, malabsorbed free
fatty acid binds calcium in the intestinal lumen to form calcium-fatty acid salts and
thus free calcium becomes less available to bind oxalate in the intestinal lumen.
Oxalate then binds with sodium to form sodium oxalate that is easily absorbed
through the colonic mucosa resulting in hyperoxaluria [58]. Uric acid stones can
also be formed in patients with diarrhea and/or intestinal neostomy, dehydration
and hypemetabolic state [59]. Crohn’s disease is also associated with IgA nephropa-
thy [60] and membranous glomerulonephritis [61]. Patients taking mesalamine can
develop interstitial nephritis. But patients with Crohn’s disease (not taking
mesalamine) can also develop primary chronic tubulointerstitial nephritis [62].
Secondary renal amyloidosis can be a late manifestation of Crohn’s disease [63].
The renal manifestations are outlined in Table 3.
7. Cardiovascular manifestations
Although different cardiovascular manifestations are seen in patients with
Crohn’s disease, they are not due to traditional cardiovascular risk factors but
secondary to chronic systemic inflammation [64]. The different cardiovascular
manifestations include pericarditis, myocarditis, nonbacterial thrombotic endocar-
ditis, congestive heart failure, arterial and venous thromboembolism. Among these
pericarditis is the most common cardiovascular manifestation [65]. Myocarditis can
be due to autoimmune mechanism secondary to exposure to autoantigen or
mesalamine-induced [66]. Crohn’s disease can also be associated with non-bacterial
thrombotic endocarditis (Libman-Sacks endocarditis) due to hypercoagulable state
[67]. The chronic inflammatory state seen in Crohn’s disease may cause myocardial
fibrosis due to abnormal collagen metabolism, microvascular endothelial dysfunc-
tion, vitamin and essential nutrient deficiencies and changes in nitric oxide








• Nephrolithiasis • Interstitial nephritis
Table 3.
Renal manifestations in Crohn’s disease.
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mediated vasodilation [68]. This may lead to chronic heart failure, atrial and ven-
tricular arrhythmia and heart block. Acute heart failure can occur secondary to
myopericarditis or myocardial infarction. Patients with Crohn’s disease are at
increased risk of developing both venous and arterial thromoboembolism because
of hypercoagulable state as active bowel inflammation leads to thrombocytosis,
increased levels of factor V, factor VIII, fibrinogen and fibrinopeptide A, and
deficiency of antithrombin III and free protein S in the blood. Other factors include
prolonged bed rest, immobility, central venous catheter placement, use of cortico-
steroids and oral contraceptive pills, smoking and dehydration [69]. The cardiovas-
cular manifestations are outlined as follows:
• Pericarditis
• Myocarditis
• Nonbacterial thrombotic endocarditis
• Increased risk of thromboembolism
8. Pulmonary manifestations
Patients with Crohn’s disease can rarely develop subclinical inflammatory pro-
cess in the lung parenchyma, tracheobronchial tree and pleura in the absence of
pulmonary symptoms [70, 71]. Increased lymphocytic count in bronchoalveolar
lavage (BAL) indicating lymphocytic alveolitis may suggest latent involvement of
lungs in Crohn’s disease [72]. Abnormal pulmonary function test (increased carbon
monoxide transfer factor/TLCO) can be found in this asymptomatic group of
patients without any abnormal imaging [73]. Lung involvement may correlate with
bowel inflammation [74]. Other pulmonary manifestations seen in association with
Crohn’s disease are tracheobronchitis, bronchiectasis, bronchiolitis obliterans orga-
nizing pneumonia (BOOP), multiple pulmonary nodules (sterile necrobiotic nod-
ules consisting of sterile aggregates of neutrophils with necrosis),
pleuropericarditis, methotrexate-induced pneumonitis, interstitial lung disease and
pulmonary eosinophilia due to sulfasalazine and mesalamine, and biologic agents
related infections such as reactivation of pulmonary tuberculosis, development of
pneumocystis carinii pneumonia and opportunistic fungal infections (aspergillosis,
coccidiomycosis, histoplasmosis, nocardiosis) [75–84]. The pulmonary manifesta-
tions are outlined in Table 4.
Pulmonary manifestations
due to disease









• Methotrexate-induced pneumonitis and interstitial lung disease
• Pulmonary eosinophilia due to sulfasalazine and mesalamine
• Reactivation of pulmonary tuberculosis, development of
pneumocystis carinii pneumonia and opportunistic fungal
infections (aspergillosis, coccidiomycosis, histoplasmosis,
nocardiosis) due biologic agents
Table 4.
Pulmonary manifestations in Crohn’s disease.
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9. Conclusion
As Crohn’s disease is a chronic systemic inflammatory disease, the inflammatory
cascade can be seen in multiple organs. Many of the EIMs occur as a result of
pro-inflammatory cytokines. Some of the EIMs do not correlate with intestinal
inflammatory activity. Some of the EIMs may precede the gastrointestinal manifes-
tations of Crohn’s disease. Some of the EIMs are due to malabsorption of nutrients,
vitamins and minerals. Some of the EIMs are due to autoantigens. Some of the EIMs
are due to medications used for Crohn’s disease.
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